Enhancement of activation-induced T cell proliferation by SIRPG in a CD47-independent manner.

Front Immunol · 2025 · PMC12678352 · PMID 41357240

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

Eta, but not cer or tocilizumab (toc, a humanized IgG1 against human IL-6R), also showed a strong trend of enhancing the expression of SIRPG in blasting CD4+ and CD8+ T cells ( Figures 2B, C , and S2C ).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.